<unk> , sold under the brand name Skyrizi, is a humanized monoclonal antibody targeting interleukin 23A (IL-23A).<unk>  is part of a collaboration between Boehringer Ingelheim and AbbVie.<unk>  has been approved in the European Union, the United States, and Canada for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. In Japan, it is approved for treating plaque psoriasis, generalized pustular psoriasis, erythrodermic psoriasis and psoriatic arthritis in adults who have an inadequate response to conventional therapies.
Risankizumab
Brolucizumab
Caplacizumab
Etaracizumab
Ixekizumab
Bimekizumab
Tildrakizumab
Mogamulizumab